胃癌组织中microRNA-210的表达与临床病理因素及预后关系的研究

doi:10.19401/j.cnki.1007-3639.2017.03.006

摘要/Abstract

摘要： 背景与目的：miR-210与胃癌的发生、发展密切相关，但其作用机制及临床意义仍不明确。该研究旨在探讨miR-210在胃癌组织中的表达情况及其临床意义。方法：采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction，RTFQ-PCR)检测78例胃癌组织及相应的癌旁组织中miR-210的表达情况，分析其与临床病理因素及预后的关系。结果：RTFQ-PCR检查结果发现，miR-210在胃癌组织中的表达高于癌旁组织，两者相比差异有统计学意义(P<0.05)。miR-210的表达与肿瘤大小、淋巴结转移及TNM分期密切相关，而与患者年龄、性别、肿瘤的分化程度及浸润深度等无关。miR-210低表达患者5年生存率为48.2%，miR-210高表达患者5年生存率为30.4%，差异有统计学意义(χ²=4.216，P=0.040)。结论：miR-210在胃癌组织中的表达明显高于癌旁正常组织，可能与胃癌的发生、发展及预后有关。miR-210有望成为胃癌新的诊断标志物及治疗靶点。

关键词: 胃癌, microRNA-210, 转移, 预后

Abstract: Background and purpose: miR-210 was closely related to the occurrence and development of gastric cancer, but its mechanism and clinical significance were still not clear. The purpose of this study was to explore the expression of miR-210 in gastric cancer tissues and its clinical significance. Methods: The expression of miR-210 was detected in gastric cancer tissues and the corresponding adjacent tissues. The relationship between the expression of miR-210 and clinical pathological factors and prognosis was analyzed. Results: Real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) showed that the expression of miR-210 in gastric cancer was higher than that in adjacent tissues, and there was a significant difference between the two groups (P<0.05). The expression of miR-210 was closely related to tumor size, lymph node metastasis and TNM stage, but was not related to age, gender, tumor differentiation and depth of invasion. The 5-year survival rate of patients with low miR-210 expression was 48.2%, whereas the 5-year survival rate of patients with high miR-210 expression was 30.4% (χ²=4.216, P=0.040). Conclusion: The expression of miR-210 in gastric cancer was higher than that in adjacent tissues, and maybe related to the development and prognosis of gastric cancer. miR-210 is expected to be a new diagnostic marker and therapeutic target for gastric cancer.

Key words: Gastric cancer, MicroRNA-210, Metastasis, Prognosis

俞鹏飞,杜义安,杨立涛,等. 胃癌组织中microRNA-210的表达与临床病理因素及预后关系的研究[J]. 中国癌症杂志, 2017, 27(3): 197-200.

YU Pengfei, DU Yian, YANG Litao, et al. Expression of microRNA-210 in gastric cancer and its relationship with clinicopathological factors and prognosis[J]. China Oncology, 2017, 27(3): 197-200.

[1]	蓝煜, 王风华. 2024晚期胃癌诊疗指南更新对比与梳理：CSCO、NCCN和ESMO[J]. 中国癌症杂志, 2025, 35(2): 219-227.
[2]	赵翊含, 李若尘, 林岩松. 甲状腺癌骨转移的诊治现状及展望[J]. 中国癌症杂志, 2025, 35(1): 12-20.
[3]	林秋玉, 王宇鑫, 林承赫. 靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景[J]. 中国癌症杂志, 2025, 35(1): 58-67.
[4]	冯欣滢, 王冰, 刘培峰. 腹膜转移癌腹腔化疗的创新与挑战[J]. 中国癌症杂志, 2024, 34(9): 827-837.
[5]	陈奕君, 刘雨航, 段海波, 王雄军. AGPAT5在肝癌中的功能与机制研究[J]. 中国癌症杂志, 2024, 34(9): 838-847.
[6]	黄浩哲, 陈红, 郑德重, 陈超, 王英, 许立超, 王耀辉, 何新红, 杨媛媛, 李文涛. 基于CT的影像组学诺模图预测结直肠癌肺转移射频消融后的局部肿瘤进展[J]. 中国癌症杂志, 2024, 34(9): 857-872.
[7]	伍雯, 张若昕, 翁俊勇, 马延磊, 蔡国响, 李心翔, 杨永志. 探索阳性淋巴结比率在ypⅢ期结直肠癌患者中的预后价值及预测模型的建立[J]. 中国癌症杂志, 2024, 34(9): 873-880.
[8]	肖锋, 许桐林, 朱琳, 肖静文, 吴天祺, 顾春燕. M1型肿瘤相关巨噬细胞在肝细胞癌组织中浸润的意义[J]. 中国癌症杂志, 2024, 34(8): 726-733.
[9]	曹晓珊, 杨蓓蓓, 丛斌斌, 刘红. 三阴性乳腺癌脑转移治疗的研究进展[J]. 中国癌症杂志, 2024, 34(8): 777-784.
[10]	姜丹, 宋国庆, 王晓丹. 乳腺癌中线粒体功能障碍与CPT1A/ERK信号转导通路共同调节乳腺癌恶性行为的机制研究[J]. 中国癌症杂志, 2024, 34(7): 650-658.
[11]	刘帅, 张凯, 张晓青, 栾巍. 派安普利单抗联合安罗替尼和化疗围手术期治疗局部进展期胃癌的探索性研究[J]. 中国癌症杂志, 2024, 34(7): 659-668.
[12]	黄思捷, 康勋, 李文斌. 鞘内注射治疗实体瘤脑膜转移的临床研究进展[J]. 中国癌症杂志, 2024, 34(7): 695-701.
[13]	唐楠, 黄慧霞, 刘晓健. 利用单细胞测序和转录组测序建立结直肠癌免疫细胞的9基因预后模型[J]. 中国癌症杂志, 2024, 34(6): 548-560.
[14]	张若昕, 叶紫岚, 翁俊勇, 李心翔. 高龄与Ⅱ期结直肠癌患者预后不良的相关性研究[J]. 中国癌症杂志, 2024, 34(5): 485-492.
[15]	汪斐, 刘佩, 胡楠. 贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究[J]. 中国癌症杂志, 2024, 34(5): 493-500.

胃癌组织中microRNA-210的表达与临床病理因素及预后关系的研究

Expression of microRNA-210 in gastric cancer and its relationship with clinicopathological factors and prognosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价